This site is intended for UK healthcare professionals

 
Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications with an arm’s length sponsorship towards the development of the British Journal of Cardiology masterclasses.
novartis-logo-transparent

Prescribing to reduce further events in chronic coronary syndrome and cardiac failure

15 January 2025
Available for 1 CPD point(s)

Masterclass

Gayle Campbell and Professor Pardeep Jhund discuss secondary prevention for heart failure patients, including key topics such as preventing reinfarction, foundational anti-failure agents, managing worsening heart failure, and improving patient adherence using tools like MedTap.
Learning objectives
  • Understand secondary prevention measures to implement to reduce the risk of further events in patients with established disease
  • Obtain an overview of the pertinent lifestyle and medical intervention strategies available to improve outcomes
  • Recognise the importance of personalised approaches to treatment to improve engagement and adherence
  • Understand engaging with older patients around technology and tools they can use to maximise these resources
Speakers

Gayle Campbell Lead Heart Failure Pharmacist, Guy’s and St Thomas’ NHS Foundation Trust
Professor Pardeep Jhund Professor of Cardiology and Epidemiology and Honorary Consultant Cardiologist, University of Glasgow

Learning module instructions

This BJC learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 75%. If less time is spent learning then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

  1. McDoniagh TA et al. Eur Heart J. 2021;42:3599–3726
  2. Mebazaa  A et al. Lancet. 2022;400:1938–1952
  3. NICE. Chronic heart failure in adults: diagnosis and management. 2018. Available at: https://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685 (accessed January 2025)

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.